Merck Betting Up To $1B On Endocyte's Cancer Treatment
Merck & Co. Inc. will pay Endocyte Inc. up to $1 billion as they partner on the production of experimental cancer treatment vintafolide, the companies announced Monday....To view the full article, register now.
Already a subscriber? Click here to view full article